Robert Kulawy

1.6k total citations
36 papers, 1.3k citations indexed

About

Robert Kulawy is a scholar working on Molecular Medicine, Pharmacology and Epidemiology. According to data from OpenAlex, Robert Kulawy has authored 36 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Molecular Medicine, 11 papers in Pharmacology and 11 papers in Epidemiology. Recurrent topics in Robert Kulawy's work include Antibiotic Resistance in Bacteria (15 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Robert Kulawy is often cited by papers focused on Antibiotic Resistance in Bacteria (15 papers), Antibiotics Pharmacokinetics and Efficacy (11 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Robert Kulawy collaborates with scholars based in United States, Canada and United Kingdom. Robert Kulawy's co-authors include George L. Drusano, Arnold Louie, Weiguo Liu, Joseph Bertino, Anne N. Nafziger, David Brown, Angela D. M. Kashuba, Mario L. Rocci, Christine Fregeau and Ashley N. Brown and has published in prestigious journals such as Antimicrobial Agents and Chemotherapy, Clinical Pharmacology & Therapeutics and PLoS Computational Biology.

In The Last Decade

Robert Kulawy

36 papers receiving 1.3k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Kulawy United States	21	515	412	402	383	238	36	1.3k
Olivier Petitjean France	22	667 1.3×	246 0.6×	330 0.8×	450 1.2×	225 0.9×	89	1.6k
Anne Schmitt‐Hoffmann Switzerland	23	451 0.9×	847 2.1×	276 0.7×	669 1.7×	227 1.0×	43	1.5k
Toshihiro Wajima Japan	23	440 0.9×	430 1.0×	358 0.9×	424 1.1×	191 0.8×	59	1.4k
Paul M. Beringer United States	22	500 1.0×	333 0.8×	286 0.7×	362 0.9×	175 0.7×	64	1.4k
Jon G. Sundelof United States	12	768 1.5×	316 0.8×	632 1.6×	343 0.9×	260 1.1×	18	1.5k
Norifumi Morikawa Japan	19	892 1.7×	486 1.2×	375 0.9×	535 1.4×	100 0.4×	101	1.4k
Michael S. Schwartz United States	22	375 0.7×	362 0.9×	160 0.4×	253 0.7×	327 1.4×	42	1.6k
Sherwin K. B. Sy United States	19	499 1.0×	135 0.3×	446 1.1×	339 0.9×	204 0.9×	83	1.1k
Denis Beauchamp Canada	25	549 1.1×	275 0.7×	208 0.5×	347 0.9×	346 1.5×	86	1.5k
Matthew L. Rizk United States	23	644 1.3×	274 0.7×	591 1.5×	411 1.1×	421 1.8×	55	1.5k

Countries citing papers authored by Robert Kulawy

Since Specialization

Citations

This map shows the geographic impact of Robert Kulawy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Kulawy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Kulawy more than expected).

Fields of papers citing papers by Robert Kulawy

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Kulawy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Kulawy. The network helps show where Robert Kulawy may publish in the future.

Co-authorship network of co-authors of Robert Kulawy

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Kulawy. A scholar is included among the top collaborators of Robert Kulawy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Kulawy. Robert Kulawy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Drusano, George L., et al.. (2017). Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system. European Journal of Pharmaceutical Sciences. 111. 443–449. 33 indexed citations

2.

Louie, Arnold, Weiguo Liu, Robert Kulawy, & George L. Drusano. (2011). In Vivo Pharmacodynamics of Torezolid Phosphate (TR-701), a New Oxazolidinone Antibiotic, against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Strains in a Mouse Thigh Infection Model. Antimicrobial Agents and Chemotherapy. 55(7). 3453–3460. 74 indexed citations

3.

Brown, Ashley N., James J. McSharry, Jonathan Adams, et al.. (2011). Pharmacodynamic Analysis of a Serine Protease Inhibitor, MK-4519, against Hepatitis C Virus Using a NovelIn VitroPharmacodynamic System. Antimicrobial Agents and Chemotherapy. 56(3). 1170–1181. 9 indexed citations

4.

Cardone, Katie E., et al.. (2011). Ertapenem Pharmacokinetics and Pharmacodynamics during Continuous Ambulatory Peritoneal Dialysis. Antimicrobial Agents and Chemotherapy. 56(2). 725–730. 13 indexed citations

5.

Louie, Arnold, Mariana Castanheira, Weiguo Liu, et al.. (2011). Pharmacodynamics of β-Lactamase Inhibition by NXL104 in Combination with Ceftaroline: Examining Organisms with Multiple Types of β-Lactamases. Antimicrobial Agents and Chemotherapy. 56(1). 258–270. 69 indexed citations

6.

Lin, Hung‐Yun, Cornelia B. Landersdorfer, David London, et al.. (2011). Pharmacodynamic Modeling of Anti-Cancer Activity of Tetraiodothyroacetic Acid in a Perfused Cell Culture System. PLoS Computational Biology. 7(2). e1001073–e1001073. 76 indexed citations

7.

Louie, Arnold, Brian VanScoy, Henry S. Heine, et al.. (2011). Differential Effects of Linezolid and Ciprofloxacin on Toxin Production by Bacillus anthracis in an In Vitro Pharmacodynamic System. Antimicrobial Agents and Chemotherapy. 56(1). 513–517. 16 indexed citations

8.

Louie, Arnold, et al.. (2010). The Combination of Meropenem and Levofloxacin Is Synergistic with Respect to both Pseudomonas aeruginosa Kill Rate and Resistance Suppression. Antimicrobial Agents and Chemotherapy. 54(6). 2646–2654. 59 indexed citations

9.

Drusano, George L., et al.. (2010). The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill ofMycobacterium tuberculosisas Determined in a Hollow-Fiber Infection Model. mBio. 1(3). 62 indexed citations

10.

McSharry, James J., et al.. (2009). Prediction of the Pharmacodynamically Linked Variable of Oseltamivir Carboxylate for Influenza A Virus Using an In Vitro Hollow-Fiber Infection Model System. Antimicrobial Agents and Chemotherapy. 53(6). 2375–2381. 39 indexed citations

11.

Louie, Arnold, Christine Fregeau, Weiguo Liu, Robert Kulawy, & George L. Drusano. (2009). Pharmacodynamics of Levofloxacin in a Murine Pneumonia Model of Pseudomonas aeruginosa Infection: Determination of Epithelial Lining Fluid Targets. Antimicrobial Agents and Chemotherapy. 53(8). 3325–3330. 27 indexed citations

12.

Drusano, George L., Ólanrewaju O. Okusanya, David Brown, et al.. (2008). Is 60 Days of Ciprofloxacin Administration Necessary for Postexposure Prophylaxis for Bacillus anthracis ?. Antimicrobial Agents and Chemotherapy. 52(11). 3973–3979. 10 indexed citations

13.

Louie, Arnold, David Brown, Weiguo Liu, et al.. (2007). In Vitro Infection Model Characterizing the Effect of Efflux Pump Inhibition on Prevention of Resistance to Levofloxacin and Ciprofloxacin in Streptococcus pneumoniae. Antimicrobial Agents and Chemotherapy. 51(11). 3988–4000. 19 indexed citations

14.

Nafziger, Anne N., et al.. (2006). Poor correlation between 6β‐hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity. British Journal of Clinical Pharmacology. 62(2). 187–195. 39 indexed citations

15.

Nafziger, Anne N., et al.. (2005). Over‐the‐Counter Progesterone Cream Produces Significant Drug Exposure Compared to a Food and Drug Administration‐Approved Oral Progesterone Product. The Journal of Clinical Pharmacology. 45(6). 614–619. 13 indexed citations

16.

Nafziger, Anne N., Shirley M. Tsunoda, Edna F. Choo, et al.. (2002). Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques. The Journal of Clinical Pharmacology. 42(4). 376–382. 45 indexed citations

17.

Nafziger, Anne N., Shirley M. Tsunoda, Edna F. Choo, et al.. (2002). Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques. The Journal of Clinical Pharmacology. 42(4). 376–382. 5 indexed citations

18.

Streetman, Daniel S., Angela D. M. Kashuba, Joseph Bertino, et al.. (2001). Use of midazolam urinary metabolic ratios for cytochrome P450 3A (CYP3A) phenotyping. Pharmacogenetics. 11(4). 349–355. 14 indexed citations

19.

Kashuba, Angela D. M., Anne N. Nafziger, Gregory L. Kearns, et al.. (1998). Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping*. Clinical Pharmacology & Therapeutics. 64(3). 257–268. 55 indexed citations

20.

Kashuba, Angela D. M., et al.. (1998). Quantification of 3-month intraindividual variability and the influence of sex and menstrual cycle phase on CYP3A activity as measured by phenotyping with intravenous midazolam*. Clinical Pharmacology & Therapeutics. 64(3). 269–277. 98 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact